Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Clinical profile of comorbidity of rare diseases in a Tunisian patient: a case report associating incontinentia pigmenti and Noonan syndrome.

Ghedira N, Lagarde A, Ben Ameur K, Elouej S, Sakka R, Kerkeni E, Chioukh FZ, Olschwang S, Desvignes JP, Abdelhak S, Delague V, Lévy N, Monastiri K, De Sandre-Giovannoli A.

BMC Pediatr. 2018 Aug 29;18(1):286. doi: 10.1186/s12887-018-1259-8.

2.

Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations.

Pujol P, Vande Perre P, Faivre L, Sanlaville D, Corsini C, Baertschi B, Anahory M, Vaur D, Olschwang S, Soufir N, Bastide N, Amar S, Vintraud M, Ingster O, Richard S, Le Coz P, Spano JP, Caron O, Hammel P, Luporsi E, Toledano A, Rebillard X, Cambon-Thomsen A, Putois O, Rey JM, Hervé C, Zorn C, Baudry K, Galibert V, Gligorov J, Azria D, Bressac-de Paillerets B, Burnichon N, Spielmann M, Zarca D, Coupier I, Cussenot O, Gimenez-Roqueplo AP, Giraud S, Lapointe AS, Niccoli P, Raingeard I, Le Bidan M, Frebourg T, Rafii A, Geneviève D.

Eur J Hum Genet. 2018 Dec;26(12):1732-1742. doi: 10.1038/s41431-018-0224-1. Epub 2018 Aug 8.

PMID:
30089825
3.

The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.

Marisa L, Svrcek M, Collura A, Becht E, Cervera P, Wanherdrick K, Buhard O, Goloudina A, Jonchère V, Selves J, Milano G, Guenot D, Cohen R, Colas C, Laurent-Puig P, Olschwang S, Lefèvre JH, Parc Y, Boige V, Lepage C, André T, Fléjou JF, Dérangère V, Ghiringhelli F, de Reynies A, Duval A.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx136.

PMID:
28922790
4.

Molecular combing reveals complex 4q35 rearrangements in Facioscapulohumeral dystrophy.

Nguyen K, Puppo F, Roche S, Gaillard MC, Chaix C, Lagarde A, Pierret M, Vovan C, Olschwang S, Salort-Campana E, Attarian S, Bartoli M, Bernard R, Magdinier F, Levy N.

Hum Mutat. 2017 Oct;38(10):1432-1441. doi: 10.1002/humu.23304. Epub 2017 Aug 6.

5.

[OISO, automatic treatment of patients management in oncogenetics].

Guien C, Fabre A, Lagarde A, Salgado D, Gensollen-Thiriez C, Zattara H, Beroud C, Olschwang S.

Bull Cancer. 2017 Jul - Aug;104(7-8):602-607. doi: 10.1016/j.bulcan.2017.06.003. Epub 2017 Jul 8. French.

6.

Improving Mutation Screening in Patients with Colorectal Cancer Predisposition Using Next-Generation Sequencing.

Rey JM, Ducros V, Pujol P, Wang Q, Buisine MP, Aissaoui H, Maudelonde T, Olschwang S.

J Mol Diagn. 2017 Jul;19(4):589-601. doi: 10.1016/j.jmoldx.2017.04.005. Epub 2017 May 11.

PMID:
28502729
7.

[Metameric macular and papular skin mastocytosis].

Maciejewski M, Debarre JM, Georgin-Lavialle S, Kettani S, Olschwang S, Guérin-Moreau M, Le Corre Y, Martin L.

Ann Dermatol Venereol. 2017 Mar;144(3):208-211. doi: 10.1016/j.annder.2016.09.041. Epub 2016 Oct 21. French.

PMID:
27776809
8.

Actionable Genes, Core Databases, and Locus-Specific Databases.

Pinard A, Miltgen M, Blanchard A, Mathieu H, Desvignes JP, Salgado D, Fabre A, Arnaud P, Barré L, Krahn M, Grandval P, Olschwang S, Zaffran S, Boileau C, Béroud C, Collod-Béroud G.

Hum Mutat. 2016 Dec;37(12):1299-1307. doi: 10.1002/humu.23112. Epub 2016 Sep 26.

PMID:
27600092
9.

Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant.

Li J, Woods SL, Healey S, Beesley J, Chen X, Lee JS, Sivakumaran H, Wayte N, Nones K, Waterfall JJ, Pearson J, Patch AM, Senz J, Ferreira MA, Kaurah P, Mackenzie R, Heravi-Moussavi A, Hansford S, Lannagan TRM, Spurdle AB, Simpson PT, da Silva L, Lakhani SR, Clouston AD, Bettington M, Grimpen F, Busuttil RA, Di Costanzo N, Boussioutas A, Jeanjean M, Chong G, Fabre A, Olschwang S, Faulkner GJ, Bellos E, Coin L, Rioux K, Bathe OF, Wen X, Martin HC, Neklason DW, Davis SR, Walker RL, Calzone KA, Avital I, Heller T, Koh C, Pineda M, Rudloff U, Quezado M, Pichurin PN, Hulick PJ, Weissman SM, Newlin A, Rubinstein WS, Sampson JE, Hamman K, Goldgar D, Poplawski N, Phillips K, Schofield L, Armstrong J, Kiraly-Borri C, Suthers GK, Huntsman DG, Foulkes WD, Carneiro F, Lindor NM, Edwards SL, French JD, Waddell N, Meltzer PS, Worthley DL, Schrader KA, Chenevix-Trench G.

Am J Hum Genet. 2016 May 5;98(5):830-842. doi: 10.1016/j.ajhg.2016.03.001. Epub 2016 Apr 14.

10.

Consideration surrounding incidental findings throughout multigene panel testing in cancer genetics.

Grandval P, Fabre AJ, Béroud C, Olschwang S.

Clin Genet. 2016 Feb;89(2):267-8. doi: 10.1111/cge.12672. Epub 2015 Oct 6. No abstract available.

PMID:
26437750
11.

Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study.

Movahedi M, Bishop DT, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar RS, Side L, Scott RJ, Thomas HJ, Vasen HF, Burn J, Mathers JC.

J Clin Oncol. 2015 Nov 1;33(31):3591-7. doi: 10.1200/JCO.2014.58.9952. Epub 2015 Aug 17.

PMID:
26282643
12.

PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer.

Manceau G, Marisa L, Boige V, Duval A, Gaub MP, Milano G, Selves J, Olschwang S, Jooste V, le Legrain M, Lecorre D, Guenot D, Etienne-Grimaldi MC, Kirzin S, Martin L, Lepage C, Bouvier AM, Laurent-Puig P.

Cancer Med. 2015 Mar;4(3):371-82. doi: 10.1002/cam4.370. Epub 2015 Feb 2.

13.

Vascular Endothelial Growth Factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer.

Sibertin-Blanc C, Mancini J, Fabre A, Lagarde A, Del Grande J, Levy N, Seitz JF, Olschwang S, Dahan L.

Dig Liver Dis. 2015 Apr;47(4):331-7. doi: 10.1016/j.dld.2014.12.013. Epub 2014 Dec 30.

PMID:
25617075
14.

Genomic variations integrated database for MUTYH-associated adenomatous polyposis.

Grandval P, Fabre AJ, Gaildrat P, Baert-Desurmont S, Blayau M, Buisine MP, Coulet F, Maugard C, Pinson S, Remenieras A, Rouleau E, Uhrhammer N, Beroud C, Olschwang S.

J Med Genet. 2015 Jan;52(1):25-7. doi: 10.1136/jmedgenet-2014-102752. Epub 2014 Nov 3. No abstract available.

PMID:
25368107
15.

Frequent intragenic rearrangements of DPYD in colorectal tumours.

van Kuilenburg AB, Etienne-Grimaldi MC, Mahamat A, Meijer J, Laurent-Puig P, Olschwang S, Gaub MP, Hennekam RC, Benchimol D, Houry S, Letoublon C, Gilly FN, Pezet D, Andre T, Faucheron JL, Abderrahim-Ferkoune A, Vijzelaar R, Pradere B, Milano G.

Pharmacogenomics J. 2015 Jun;15(3):211-8. doi: 10.1038/tpj.2014.68. Epub 2014 Oct 28.

PMID:
25348620
16.

Clinical Utility Gene Card for: Familial adenomatous polyposis (FAP) and attenuated FAP (AFAP)--update 2014.

Aretz S, Vasen HF, Olschwang S.

Eur J Hum Genet. 2015 Jun;23(6). doi: 10.1038/ejhg.2014.193. Epub 2014 Sep 24. No abstract available.

17.

Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study.

Etienne-Grimaldi MC, Mahamat A, Chazal M, Laurent-Puig P, Olschwang S, Gaub MP, Formento JL, Formento P, Sudaka A, Boige V, Abderrahim-Ferkoune A, Benchimol D, André T, Houry S, Faucheron JL, Letoublon C, Gilly FN, Delpero JR, Lasser P, Pradere B, Pezet D, Penault-Llorca F, Milano G.

Br J Cancer. 2014 May 27;110(11):2728-37. doi: 10.1038/bjc.2014.213. Epub 2014 May 6.

18.

High-resolution analysis of DNA copy number alterations in rectal cancer: correlation with metastasis, survival, and mRNA expression.

Doyen J, Letouzé E, Marisa L, de Reyniès A, Milano G, Etienne-Grimaldi MC, Olschwang S, Gaedcke J, Ghadimi M, Gérard JP.

Strahlenther Onkol. 2014 Oct;190(11):1028-36. doi: 10.1007/s00066-014-0659-4. Epub 2014 Apr 26.

PMID:
24770938
19.

The UMD-APC database, a model of nation-wide knowledge base: update with data from 3,581 variations.

Grandval P, Blayau M, Buisine MP, Coulet F, Maugard C, Pinson S, Remenieras A, Tinat J, Uhrhammer N, Béroud C, Olschwang S.

Hum Mutat. 2014 May;35(5):532-6. doi: 10.1002/humu.22539. Epub 2014 Apr 7.

PMID:
24599579
20.

A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.

Beau-Faller M, Blons H, Domerg C, Gajda D, Richard N, Escande F, Solassol J, Denis MG, Cayre A, Nanni-Metellus I, Olschwang S, Lizard S, Piard F, Pretet JL, de Fraipont F, Bièche I, de Cremoux P, Rouquette I, Bringuier PP, Mosser J, Legrain M, Voegeli AC, Saulnier P, Morin F, Pignon JP, Zalcman G, Cadranel J.

J Mol Diagn. 2014 Jan;16(1):45-55. doi: 10.1016/j.jmoldx.2013.07.009. Epub 2013 Oct 30.

PMID:
24183959
21.

Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.

Pujol P, Lyonnet DS, Frebourg T, Blin J, Picot MC, Lasset C, Dugast C, Berthet P, de Paillerets BB, Sobol H, Grandjouan S, Soubrier F, Buecher B, Guimbaud R, Lidereau R, Jonveaux P, Houdayer C, Giraud S, Olschwang S, Nogue E, Galibert V, Bara C, Nowak F, Khayat D, Nogues C.

Breast Cancer Res Treat. 2013 Aug;141(1):135-44. doi: 10.1007/s10549-013-2669-9. Epub 2013 Aug 24.

PMID:
23974829
22.

UMD-MLH1/MSH2/MSH6 databases: description and analysis of genetic variations in French Lynch syndrome families.

Grandval P, Fabre AJ, Gaildrat P, Baert-Desurmont S, Buisine MP, Ferrari A, Wang Q, Béroud C, Olschwang S.

Database (Oxford). 2013 May 31;2013:bat036. doi: 10.1093/database/bat036. Print 2013.

23.

Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.

Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Ayadi M, Kirzin S, Chazal M, Fléjou JF, Benchimol D, Berger A, Lagarde A, Pencreach E, Piard F, Elias D, Parc Y, Olschwang S, Milano G, Laurent-Puig P, Boige V.

PLoS Med. 2013;10(5):e1001453. doi: 10.1371/journal.pmed.1001453. Epub 2013 May 21.

24.

[Desmoid tumors in children: current strategy].

Oudot C, Defachelles AS, Minard-Colin V, Olschwang S, Fourcade L, Helfre S, Orbach D.

Bull Cancer. 2013 May;100(5):518-28. doi: 10.1684/bdc.2013.1747. Review. French.

PMID:
23695183
25.

Gastric adenocarcinoma in familial adenomatous polyposis can occur without previous lesions.

Ravoire A, Faivre L, Degrolard-Courcet E, Bedenne L, Olschwang S, Rat P, Ortega-Deballon P.

J Gastrointest Cancer. 2014 Sep;45(3):377-9. doi: 10.1007/s12029-013-9504-8. No abstract available.

PMID:
23677534
26.

Design of a core classification process for DNA mismatch repair variations of a priori unknown functional significance.

Grandval P, Fabre AJ, Olschwang S.

Hum Mutat. 2013 Jun;34(6):920-2. doi: 10.1002/humu.22312. Epub 2013 Mar 28. No abstract available.

PMID:
23554159
27.

Semiparametric inference on the penetrances of rare genetic mutations based on a case-family design.

Zhang H, Zeng D, Olschwang S, Yu K.

J Stat Plan Inference. 2013 Feb;143(2):368-377.

28.

Towards a "Lyon molecular signature" to individualize the treatment of rectal cancer. Prognostic analysis of a prospective cohort of 94 rectal cancers T1-2-3 Nx MO to be the basis of a molecular signature.

Gérard JP, Baulieux J, Doyen J, Gal J, Letouze E, Olschwang S, Chapet O, Romestaing P.

Cancer Radiother. 2012 Dec;16(8):688-96. doi: 10.1016/j.canrad.2012.09.003. Epub 2012 Nov 13.

PMID:
23153504
29.

Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.

Mathers JC, Movahedi M, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans G, Maher ER, Bertario L, Bisgaard ML, Dunlop M, Ho JW, Hodgson S, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen H, Gerdes AM, Barker G, Crawford G, Elliott F, Pylvanainen K, Wijnen J, Fodde R, Lynch H, Bishop DT, Burn J; CAPP2 Investigators.

Lancet Oncol. 2012 Dec;13(12):1242-9. doi: 10.1016/S1470-2045(12)70475-8. Epub 2012 Nov 7.

30.

A seven-gene signature aggregates a subgroup of stage II colon cancers with stage III.

Laibe S, Lagarde A, Ferrari A, Monges G, Birnbaum D, Olschwang S; COL2 Project.

OMICS. 2012 Oct;16(10):560-5. doi: 10.1089/omi.2012.0039. Epub 2012 Aug 23.

PMID:
22917480
31.

Clinical utility gene card for: Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) - update 2012.

Rahner N, Steinke V, Schlegelberger B, Eisinger F, Hutter P, Olschwang S.

Eur J Hum Genet. 2013 Jan;21(1). doi: 10.1038/ejhg.2012.164. Epub 2012 Aug 15. No abstract available.

32.

Is the controversy on breast cancer as part of the Lynch-related tumor spectrum still open?

Grandval P, Barouk-Simonet E, Bronner M, Buisine MP, Moretta J, Tinat J, Olschwang S.

Fam Cancer. 2012 Dec;11(4):681-3. doi: 10.1007/s10689-012-9562-2.

PMID:
22890886
33.

8q24 Cancer risk allele associated with major metastatic risk in inflammatory breast cancer.

Bertucci F, Lagarde A, Ferrari A, Finetti P, Charafe-Jauffret E, Van Laere S, Adelaide J, Viens P, Thomas G, Birnbaum D, Olschwang S.

PLoS One. 2012;7(5):e37943. doi: 10.1371/journal.pone.0037943. Epub 2012 May 29.

34.

Expression Profiles in Stage II Colon Cancer According to APC Gene Status.

Birnbaum DJ, Laibe S, Ferrari A, Lagarde A, Fabre AJ, Monges G, Birnbaum D, Olschwang S; COL2 Project.

Transl Oncol. 2012 Apr;5(2):72-6. Epub 2012 Apr 1.

35.

KRAS mutation spectrum notably diverges between non-small cell lung and colorectal carcinomas.

Compagnone M, Chetaille B, Olschwang S.

J Thorac Oncol. 2012 Apr;7(4):773-4; author reply 774. doi: 10.1097/JTO.0b013e318245a9c5. No abstract available.

36.

Colon-specific phenotype in Lynch syndrome associated with EPCAM deletion.

Grandval P, Baert-Desurmont S, Bonnet F, Bronner M, Buisine MP, Colas C, Noguchi T, North MO, Rey JM, Tinat J, Toulas C, Olschwang S.

Clin Genet. 2012 Jul;82(1):97-9. doi: 10.1111/j.1399-0004.2011.01826.x. Epub 2012 Jan 16. No abstract available.

PMID:
22243433
37.

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.

Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen HF, Barker G, Crawford G, Elliott F, Movahedi M, Pylvanainen K, Wijnen JT, Fodde R, Lynch HT, Mathers JC, Bishop DT; CAPP2 Investigators.

Lancet. 2011 Dec 17;378(9809):2081-7. doi: 10.1016/S0140-6736(11)61049-0. Epub 2011 Oct 27.

38.

SMAD4 protein expression and cell proliferation in colorectal adenocarcinomas.

Handra-Luca A, Olschwang S, Fléjou JF.

Virchows Arch. 2011 Nov;459(5):511-9. doi: 10.1007/s00428-011-1152-4. Epub 2011 Oct 16.

PMID:
22002709
39.

Evaluation of guidelines for management of familial adenomatous polyposis in a multicenter pediatric cohort.

Munck A, Gargouri L, Alberti C, Viala J, Peuchmaur M, Lenaerts C, Michaud L, Lamireau T, Mougenot JF, Dabadie A, Maurage C, Lachaux A, Scaillon M, Languepin J, Spyckerelle C, Meyer M, Olschwang S.

J Pediatr Gastroenterol Nutr. 2011 Sep;53(3):296-302. doi: 10.1097/MPG.0b013e3182198f4d.

PMID:
21865978
40.

First large rearrangement in the MUTYH gene and attenuated familial adenomatous polyposis syndrome.

Rouleau E, Zattara H, Lefol C, Noguchi T, Briaux A, Buecher B, Bourdon V, Sobol H, Lidereau R, Olschwang S.

Clin Genet. 2011 Sep;80(3):301-3. doi: 10.1111/j.1399-0004.2011.01699.x. No abstract available.

PMID:
21815886
41.

The LKB1 complex-AMPK pathway: the tree that hides the forest.

Sebbagh M, Olschwang S, Santoni MJ, Borg JP.

Fam Cancer. 2011 Sep;10(3):415-24. doi: 10.1007/s10689-011-9457-7. Review.

42.

Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.

Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, Guimbaud R, Buecher B, Bignon YJ, Caron O, Colas C, Noguès C, Lejeune-Dumoulin S, Olivier-Faivre L, Polycarpe-Osaer F, Nguyen TD, Desseigne F, Saurin JC, Berthet P, Leroux D, Duffour J, Manouvrier S, Frébourg T, Sobol H, Lasset C, Bonaïti-Pellié C; French Cancer Genetics Network.

JAMA. 2011 Jun 8;305(22):2304-10. doi: 10.1001/jama.2011.743.

PMID:
21642682
43.

Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).

Beau-Faller M, Degeorges A, Rolland E, Mounawar M, Antoine M, Poulot V, Mauguen A, Barbu V, Coulet F, Prétet JL, Bièche I, Blons H, Boyer JC, Buisine MP, de Fraipont F, Lizard S, Olschwang S, Saulnier P, Prunier-Mirebeau D, Richard N, Danel C, Brambilla E, Chouaid C, Zalcman G, Hainaut P, Michiels S, Cadranel J.

J Thorac Oncol. 2011 Jun;6(6):1006-15. doi: 10.1097/JTO.0b013e318211dcee.

44.

The educational role of external quality assessment in genetic testing: a 7-year experience of the European Molecular Genetics Quality Network (EMQN) in Lynch syndrome.

Qiu J, Hutter P, Rahner N, Patton S, Olschwang S.

Hum Mutat. 2011 Jun;32(6):696-7. doi: 10.1002/humu.21493. Epub 2011 Apr 5. No abstract available.

PMID:
21387467
45.

Clinical utility gene card for: familial adenomatous polyposis (FAP) and attenuated FAP (AFAP).

Aretz S, Vasen HF, Olschwang S.

Eur J Hum Genet. 2011 Jul;19(7). doi: 10.1038/ejhg.2011.7. Epub 2011 Feb 2. No abstract available.

46.

BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer.

Qiu J, Compagnone M, Laibe S, Lagarde A, Goncalves A, Turrini O, Xerri L, Monges G, Olschwang S.

Cancer Genomics Proteomics. 2011 Jan-Feb;8(1):15-8.

PMID:
21289333
47.

A quality control program for mutation detection in KIT and PDGFRA in gastrointestinal stromal tumours.

Hostein I, Debiec-Rychter M, Olschwang S, Bringuier PP, Toffolati L, Gonzalez D, Forget S, Escande F, Morzuch L, Tamborini E, Faur N, Pilotti S, Dei Tos P, Emile JF, Coindre JM.

J Gastroenterol. 2011 May;46(5):586-94. doi: 10.1007/s00535-011-0375-0. Epub 2011 Feb 1.

PMID:
21286759
48.

SMARCB1/INI1 germline mutations contribute to 10% of sporadic schwannomatosis.

Rousseau G, Noguchi T, Bourdon V, Sobol H, Olschwang S.

BMC Neurol. 2011 Jan 24;11:9. doi: 10.1186/1471-2377-11-9.

49.

[Hereditary colorectal cancer].

Olschwang S, Monges G.

Rev Prat. 2010 Oct 20;60(8):1068-70. French. No abstract available.

PMID:
21197734
50.

Leiden Open Variation Database of the MUTYH gene.

Out AA, Tops CM, Nielsen M, Weiss MM, van Minderhout IJ, Fokkema IF, Buisine MP, Claes K, Colas C, Fodde R, Fostira F, Franken PF, Gaustadnes M, Heinimann K, Hodgson SV, Hogervorst FB, Holinski-Feder E, Lagerstedt-Robinson K, Olschwang S, van den Ouweland AM, Redeker EJ, Scott RJ, Vankeirsbilck B, Grønlund RV, Wijnen JT, Wikman FP, Aretz S, Sampson JR, Devilee P, den Dunnen JT, Hes FJ.

Hum Mutat. 2010 Nov;31(11):1205-15. doi: 10.1002/humu.21343.

PMID:
20725929

Supplemental Content

Loading ...
Support Center